None

Ponatinib (Ponatinib) has been approved by the U.S. Food and Drug Administration (FDA) to be marketed under the trade name Iclusig, and has also been approved by the European Medicines Agency (EMA). The original drug of ponatinib has not yet been marketed in China. Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor indicated for the treatment of adult patients with chronic-phase, accelerated-phase, or blast-phase chronic myeloid leukemia (CML) who are resistant to or intolerant to prior tyrosine kinase inhibitor therapy, or adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ALL) who are resistant to or intolerant to prior tyrosine kinase inhibitor therapy.